National Institutes of Health, a Component of the US Dept. of Health & Human Services

Abcellera Biologies Inc.

Korea Center for Disease Control and Prevention

Abcellera Biologics Inc.

Lingshu Wang

Barney S Graham

Wei Shi

John R Mascola

Kizzmekia S Corbett

Masaru Kanekiyo

John Mascola

Julie Ledgerwood

Julian Davies

Wing-Pui Kong

Bryan Edward Jones

Christopher Carl Frye

Qing Chai

Jeffrey Streetman Boyles

Jörg Hendle

Olubukola Abiona

John Michael Sauder

Wing-pui Kong

Kevin Jepson

Anna Pustilnik

Ester Falconer

Yi Zhang

Denisa Foster

Stefanie Zentelis

Kathryn Westendorf

Krithika Muthuraman

Ganapathy Gopalrathnam

Michael Gordon Joyce

Jeffrey C Boyington

Hadi M Yassine

Syed M Moin

Kayvon Modjarrad

Theodore C Pierson

Kimberly A Dowd

Eun Sung Yang

Christina R Demaso

Rebecca S Pelc

Adrian Creanga

Leda R Castilho

Sungsoon Kim

Janghoon Choi

Hansaem Lee

Sung-youl Ko

Antibodies that bind SARS-CoV spike protein, SARS-CoV-2 spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.

Anti-coronavirus antibodies and methods of use

The present invention relates to monoclonal antibodies for a spike protein of the Middle East respiratory syndrome coronavirus (MERS-CoV), and a use thereof. Particularly, monoclonal antibodies 77-A5, 77-A6, 90-A3, 90-A9, 90-B2, 90-B7, 90-C4, 90-E5, 90-E6, 90-F1 and 90-F2 according to the present invention have excellent attachment force with respect to a full-length spike protein of MERS-CoV and the S1 domain of the protein, and, of the monoclonal antibodies, the monoclonal antibodies 90-F1, 90-E5, 90-E6, 90-F2, 77-A5 and 77-A6 have excellent attachment force with respect to an RBD antigen of MERS-CoV. Also, the antibodies 77-A5, 77-A6, 90-E5, 90-E6, 90-F1 and 90-F2 exhibit neutralizing capacity with respect to a MERS pseudovirus and MERS-CoV, and the antibodies 90-B2 and 90-B7 exhibit neutralizing capacity only with respect to MERS-CoV. Further, the monoclonal antibodies have a particular monomeric form, and have excellent stability and thus may be useful for treating or diagnosing MERS.

Monoclonal antibody for spike protein of middle east respiratory syndrome coronavirus, and use thereof

Vaccines that elicit broadly protective anti-influenza antibodies. The vaccines comprise nanoparticles that display HA trimers from Group 2 influenza virus on their surface. The nanoparticles are fusion proteins comprising a monomeric subunit (e.g., ferritin) joined to stabilized stem regions of Group 2 influenza virus HA proteins. The fusion proteins self-assemble to form the HA-displaying nanoparticles. Also provided are fusion proteins, and nucleic acid molecules encoding such proteins, and assays using nanoparticles of the invention to detect anti-influenza antibodies.

Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof

Antibodies that bind SARS-CoV Spike protein, SARS-CoV-2 Spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.

The present invention relates to a vaccine for Zika virus, the vaccine comprising Zika virus membrane and envelope proteins. More specifically, the vaccine comprises nucleic acid molecules encoding modified Zika virus membrane and/or envelope proteins. When introduced into a cell, the encoded proteins are produced, which results in the production of a virus-like particle capable of eliciting an immune response against Zika virus.

Zika virus vaccines

Methods of inducing an immune response in a subject to the Middle East respiratory syndrome coronavirus (MERS-CoV) are provided. In several embodiments, the immune response is a protective immune response that inhibits or prevents MERS-CoV infection in the subject. Recombinant MERS-CoV polypeptides and nucleic acid molecules encoding same are also provided. Additionally, neutralizing antibodies that specifically bind to MERS-CoV S protein and antigen binding fragments thereof are disclosed. The antibodies and antigen binding fragments are useful, for example, in methods of detecting MERS-CoV S protein in a sample or in a subject, as well as methods of preventing and treating a MERS-CoV infection in a subject.

Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use

Growing community of inventors

North Potomac, MD, United States of America

Lingshu Wang